RAS diseases in children

Haematologica

Volumn 99, Issue 11, 2014, Pages 1653-1662

  Niemeyer, Charlotte M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; B RAF KINASE; BUSULFAN; CBL PROTEIN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; JANUS KINASE 2; JANUS KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NEUROFIBROMIN; NUCLEOPORIN 98; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR HOXA9; UNINDEXED DRUG; MITOGEN ACTIVATED PROTEIN KINASE;

AUTOIMMUNE THROMBOCYTOPENIA; CANCER CHEMOTHERAPY; CARDIOFACIOCUTANEOUS SYNDROME; CELL PROLIFERATION; CHILD; COSTELLO SYNDROME; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENETIC DISORDER; GERMLINE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; INTRACELLULAR SIGNALING; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MYELOPROLIFERATIVE DISORDER; NOONAN SYNDROME; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UNIPARENTAL DISOMY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; INFANT; METABOLISM; NEOPLASMS; PRESCHOOL CHILD; SYNDROME;

CHILD; CHILD, PRESCHOOL; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INFANT; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION; SYNDROME;

EID: 84908399432     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.114595     Document Type: Review

References (104)

1. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras Back in the Ring. Cancer Cell. 2014;25:272-81
2. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Current Opinion in Genetics & Development. 2009;19:230-6
3. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381: 333-42
4. Aoki Y, Matsubara Y. Ras/MAPK syndromes and childhood hemato-oncological diseases. Int J Hematol. 2013;97:30-6
5. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124-33
6. Shaw AC, Kalidas K, Crosby AH, Jeffery S, 1660 Patton MA. The natural history of Noonan syndrome: a long-term follow-up study. Archives of Disease in Childhood. 2007; 92:128-132
7. Sharland M, Burch M, McKenna WM, Paton MA. A Clinical-Study of Noonan Syndrome. Archives of Disease in Childhood. 1992;67: 178-183
8. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555-1563
9. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39:70-74
10. Tartaglia M, Pennacchio LA, Zhao C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39:75-79
11. Schubbert S, Bollag G, Lyubynska N, et al. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol. 2007;27:7765-7770
12. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007-1012
13. Razaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39:1013-107
14. Cirstea IC, Kutsche K, Dvorsky R, et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet. 2010;42:27-29
15. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause develophaematologica | 2014; 99(11) mental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42:794-800
16. Matsuda K, Taira C, Sakashita K, et al. Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations. Blood. 2010;115:5429-5431
17. Cordeddu V, Di Schiavi E, Pennacchio LA, et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009;41:1022-1026
18. Hennekam RC. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet. 2003;117C:42-48
19. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-onco-gene cause Costello syndrome. Nat Genet. 2005;37:1038-4100
20. Rodriguez-Viciana P, Tetsu O, Tidyman WE, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311:1287-1290
21. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-faciocutaneous syndrome. Nat Genet. 2006;38:294-296
22. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39:1120-1126
23. Quaio CR, Carvalho JF, da Silva CA, et al. Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies. Am J Med Genet A. 2012;158A:1077-1082
24. Bader-Meunier B, Cave H, Jeremiah N, et al. Are RASopathies new monogenic predis posing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum. 2013;43:217-219
25. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011;157C:83-89
26. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm Res. 2009;72(Suppl 2):8-14
27. Bader-Meunier B, Tchernia G, Mielot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997;130:885-889
28. Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia andNoonan syndrome. J Pediatr Hematol Oncol. 1999;21:523-527
29. Tartaglia M, Niemeyer CM, Song X, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148-150
30. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood. 2005;106:2183-2185
31. Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 19991027-19991032
32. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89:3534-3543
33. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93:459-466
34. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood. 1995;85:1742-1750
35. Karow A, Baumann I, Niemeyer CM. Morphologic differential diagnosis of juvenile myelomonocytic leukemia--pitfalls apart from viral infection. J Pediatr Hematol.Oncol. 2009;31:380
36. Yoshimi A, Kamachi Y, Imai K, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer. 2013;60:836-841
37. Unal S, Cetin M, Kutlay NY, et al. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia. Ann Hematol. 2010;89:359-3564
38. Borkhardt A, Bojesen S, Haas OA, et al. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA. 2000; 97:9168-9173
39. Rottgers S, Gombert M, Teigler-Schlegel A, et al. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia. 2010;24:1197-1200
40. Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007;21:1104-1118
41. Mizoguchi Y, Fujita N, Taki T, Hayashi Y, Hamamoto K. Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98HOXA11 fusion. Am J Hematol. 2009;84: 295-297
42. Bresolin S, Zecca M, Flotho C, et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol. 2010;28:1919-1927
43. Olk-Batz C, Poetsch AR, Nollke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011;117:4871-4880
44. Flotho C, Valcamonica S, Mach-Pascual S, et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13:32-37
45. Busque L, Gilliland DG, Prchal JT, et al. Clonality in juvenile chronic myelogenous leukemia. Blood. 1995;85:21-30
46. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925-929
47. Kotecha N, Flores NJ, Irish JM, et al. Single cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14:335-343
48. Hasegawa D, Bugarin C, Giordan M, et al. Validation of flow cytometric phosphor STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia. Blood Cancer J. 2013;3:e160
49. Gandre-Babbe S, Paluru P, Aribeana C, et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood. 2013;121:4925-4929
50. Perez B, Kosmider O, Cassinat B, et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:460-468
51. Yoshida N, Yagasaki H, Xu YY, et al. Correlation of Clinical Features With the Mutational Status of GM-CSF Signaling Pathway-Related Genes in Juvenile Myelomonocytic Leukemia. Pediatr Res. 2009;65:334-340
52. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12: 144-148
53. Stephens K, Weaver M, Leppig KA, et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood. 2006;108:1684-1689
54. Flotho C, Steinemann D, Mullighan CG, et al. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. Oncogene. 2007;26:5816-5821
55. Steinemann D, Arning L, Praulich I, et al. Mitotic recombination and compound-heterozygous mutations are predominant NF1inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1. Haematologica. 2010; 95:320-323
56. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243-4250
57. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103:2325-2331
58. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441-50
59. Fragale A, Tartaglia M, Wu J, Gelb BD. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat. 2004;23:267-277
60. Niihori T, Aoki Y, Ohashi H, et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet. 2005;50:192-202
61. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell. 2005;7:179-191
62. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10:849-857
63. Miyauchi J, Asada M, Sasaki M, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248-2254
64. Reimann C, Arola M, Bierings M, et al. A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukemia. 2006; 20:1637-1638
65. Kato M, Yasui N, Seki M, et al. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy. J Pediatr. 2013;162(6):1285-1288, 1288.e1
66. Matsuda K, Nakazawa Y, Sakashita K, et al. Acquisition of loss of the wild-type NRAS 1661 locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica. 2007;92:1576-1578
67. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101:597-602
68. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest. 2004;113:528-538
69. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human non-malignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117(10):2883-2886
70. Takagi M, Shinoda K, Piao JH, et al. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. Blood. 2011;117:2887-2890
71. Lanzarotti N, Bruneau J, Trinquand A, et al. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. Blood. 2014;123:1960-1963
72. Matsuda K, Sakashita K, Taira C, et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2010;148:593-599
73. Doisaki S, Muramatsu H, Hama A, et al. A favorable outcome in children with juvenile myelomonocytic leukemia (JMML) with RAS mutations [abstract]. Blood. 2010; 116:21
74. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009;114: 1859-1863
75. Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood. 2010;115:1969-1975
76. Perez B, Mechinaud F, Galambrun C, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J Med Genet. 2010;47:686-691
77. Shiba N, Kato M, Park MJ, et al. CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome. Leukemia. 2010;24:1090-1092
78. Martinelli S, De Luca A, Stellacci E, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. 2010;87:250-257
79. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res. 2010;70:4789-4794
80. Naramura M, Jang IK, Kole H, et al. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol. 2002;3:1192-1199
81. Kitaura Y, Jang IK, Wang Y, et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases cbl and Cbl-b. Immunity. 2007;26:567-578
82. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45:937-941
83. Hirabayashi S, Flotho C, Moetter J, et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood. 2012;119:e96-e99
84. Sugimoto Y, Muramatsu H, Makishima H, et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol. 2010;150: 83-7
85. Masunaga A, Mitsuya T, Kadofuku T, et al. Mutation analysis of AML1 gene in pediatric primary myelodysplastic syndrome and juvenile myelomonocytic leukemia. Leuk Res. 2008;32:995-997
86. Zecca M, Bergamaschi G, Kratz C, et al. JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. Leukemia. 2007;21:367-369
87. Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155-162
88. de Vries AC, Stam RW, Schneider P, et al. Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. Haematologica. 2007;92: 1557-1560
89. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the WOG-MDS/EBMT trial. Blood. 2005;105:410-419
90. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia. 2002;16:645-649
91. Locatelli F, Crotta A, Ruggeri A, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013;122:2135-2141
92. Yabe M, Sako M, Yabe H, et al. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant. 2008;12:862-867
93. Dvorak CC, Loh ML. Juvenile Myelomonocytic Leukemia: Molecular Pathogenesis Informs Current Approaches to Therapy and Hematopoietic Cell Transplantation. Front Pediatr. 2014;2:25
94. Locatelli F, Niemeyer C, Angelucci E, et al. Allogenic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol. 1997;15:566-573
95. Yoshimi A, Niemeyer CM, Bohmer V, et al. Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;129:542-549
96. Tanoshima R, Goto H, Yanagimachi M, et al. Graft versus leukemia effect against juvenile myelomonocytic leukemia after unrelated cord blood transplantation. Pediatr Blood Cancer. 2008;50:665-667
97. Matthes-Martin S, Mann G, Peters C, et al. Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant. 2000;26: 377-382
98. Yoshimi A, Mohamed M, Bierings M, et al. Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia. Leukemia. 2007;21:556-560
99. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113:2867-2868
100. Cseh A, Niemeyer CM, Catalá A, et al. Therapy with azacitidine in pediatric MDS and JMML A retrospective survey of the EWOG-MDS study. [abstract]. Haematologica 2012;97 (s3):S6
101. Castleberry R, Mignon L, Jayaprakash N, et al. Phase II Window study of the farnesyltransferase inhibitor R115777 (Zarnestra®) in untreated juvenile myelomonocytic leukemia (JMML): a children's oncology group study. [abstract]. Blood. 2005;106(11): 2587
102. Lito P, Rosen N, Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013;19:1401-1409
103. Chang T, Krisman K, Theobald EH, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123:335-339
104. Lyubynska N, Gorman MF, Lauchle JO, et al. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med. 2011;3:76ra27